InspireMD Ltd.
321 Columbus Avenue
Boston
Massachusetts
02116
Tel: 857-305-2410
Website: http://www.inspire-md.com/
Email: info@inspire-md.com
198 articles about InspireMD Ltd.
-
InspireMD Announces Closing of an Upsized $20.7 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option
2/8/2021
InspireMD, Inc. ("InspireMD") (NYSE:NSPR), a medical device company focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East and Asia, today announced the closing of an upsized underwritten public offering of units for gross proceeds of approximately $20.7 million,
-
InspireMD Announces Third Quarter 2020 Financial Results
11/9/2020
InspireMD, Inc., developer of the CGuard™ Embolic Prevention System for the prevention of stroke caused by the treatment of Carotid Artery Disease, announced financial and operating results for the third quarter ended September 30, 2020.
-
UPDATE - InspireMD, Inc. Appoints Andrea Tommasoli Senior Vice President of Global Sales and Marketing and Reports Inducement Grants Under NYSE American Company Guide §711(a)
11/3/2020
InspireMD, Inc. (NYSE American: NSPR) (“Company”), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease (CAD), today announces the appointment of Andrea Tommasoli as senior vice president of global sales and marketing. Mr. Tommasoli has more than 20 years of experience in commercializing innovative medical technology solutions that improve and advance standards of care. He
-
InspireMD, Inc. Appoints Andrea Tommasoli Senior Vice President of Global Sales and Marketing and Reports Inducement Grants Under NYSE American Company Guide §711(a)
11/3/2020
InspireMD, Inc., the developer of the CGuard™ Embolic Prevention System for the prevention of stroke caused by carotid artery disease, announces the appointment of Andrea Tommasoli as senior vice president of global sales and marketing.
-
InspireMD to Report Third Quarter 2020 Financial Results on Monday, November 9, 2020 and Provide Corporate Update
11/2/2020
InspireMD, Inc., the developer of the CGuard™ Embolic Prevention System for the prevention of stroke caused by carotid artery disease, announces it will report fiscal third quarter 2020 financial results on Monday, November 9, 2020 before the market opens.
-
InspireMD Announces Renowned Interventional Cardiologist Gary S. Roubin, M.D., Ph.D., to Join Board of Directors
10/13/2020
InspireMD, Inc., the developer of the CGuard™ Embolic Prevention System for the prevention of stroke caused by carotid artery disease, announced the addition of Gary Roubin, M.D., Ph.D., to InspireMD’s Board of Directors.
-
InspireMD, Inc. Appoints Patrick Jamnik as Vice President of Business Development and Strategic Initiatives and Reports Inducement Grants Under NYSE American Company Guide §711(a)
10/6/2020
InspireMD, Inc., the developer of the CGuard™ Embolic Prevention System for the prevention of stroke caused by carotid artery disease, announced the appointment of Patrick Jamnik as vice president, business development and strategic initiatives.
-
InspireMD Announces Christina Brennan, M.D., MBA to Serve in Advisory Role for Pivotal Study of CGuard Carotid Stent System
9/10/2020
InspireMD, Inc. announced the addition of Dr. Christina Brennan as a strategic advisor to the company to assist with planning and execution of a pivotal study of the CGuard™ Carotid Stent System, CARENET-III, for prevention of stroke in patients in the United States.
-
InspireMD Announces Approval of Investigational Device Exemption (IDE) for Pivotal Study of CGuard Carotid Stent System
9/8/2020
IDE Approval to Pave the Way for Pivotal Study of CGuard System for Carotid Artery Disease and Stroke Prevention in the United States
-
InspireMD Announces the European Society of Cardiology 2020 “Best Poster Award” for Updated Data from the PARADIGM-EXTEND Study
9/3/2020
InspireMD, Inc. announces the award for Best ESC Congress Poster for the presentation of updated data from the large, long-term PARADIGM-EXTEND study of the CGuard™ Embolic Prevention System, as part of the European Society of Cardiology 2020 Carotid Update e-presentation at the European Society of Cardiology Congress 2020.
-
InspireMD to Present at the LD Micro 500 Virtual Conference on September 3, 2020
8/25/2020
InspireMD, Inc. announced that Marvin Slosman, President and Chief Executive Officer, will give a virtual corporate presentation at the LD Micro 500 taking place online on Thursday, September 3, 2020 at 4:20 PM EST followed by a live Q&A session with registered investors and other conference attendees.
-
InspireMD Regains Compliance with NYSE AMERICAN Listing Standards
8/10/2020
InspireMD, Inc., developer of the CGuard™ Embolic Prevention System for the prevention of stroke caused by the treatment of carotid artery disease, announced that as of August 7, 2020, the Company has regained compliance with the NYSE American’s continued listing standards.
-
InspireMD Announces Second Quarter 2020 Financial Results
8/5/2020
In the second quarter the Company was granted approval to market itsCGuard™ MicroNet stent in Brazil and completed an $11.5 million capital raise; reported outstanding results in studies treating patients with the CGuard™ MicroNET stent
-
UPDATE: InspireMD to Report Second Quarter 2020 Financial Results on Wednesday, August 5, 2020 and Provide Corporate UpdateConference Call to be held Wednesday, August 5, 2020 at 8:30am ET
7/29/2020
InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease (CAD), today announces it will report fiscal second quarter 2020 financial results on Wednesday, August 5, 2020 at 8:00 AM ET. Management will host a conference call at 8:30AM ET, to review financial results and provide an update on corporate developments. Following management’s fo
-
InspireMD to Report Second Quarter 2020 Financial Results on Wednesday, August 5, 2020 and Provide Corporate UpdateConference Call to be held Thursday, August 5, 2020 at 8:30am ET
7/28/2020
InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease (CAD), today announces it will report fiscal second quarter 2020 financial results on Wednesday, August 5, 2020 at 8:00 AM ET. Management will host a conference call at 8:30AM ET, to review financial results and provide an update on corporate developments. Following management’s fo
-
InspireMD Gains Registration Clearance of its CGuard™ Embolic Prevention System (EPS) in Brazil
7/23/2020
InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease (CAD), today announced it has obtained registration from the Brazilian registration authority, Agéncia Nacional de Vigiláncia Sanitária (ANVISA), for its CGuard™ MicroNet ® - covered stent, clearing it for sale and distribution in Brazil. “As the largest market for medical devices i
-
Clinical Catch-Up: June 22-26
6/29/2020
It was a busy week for clinical trial updates. Here’s a look. -
InspireMD Announces Late-Breaking Presentation of Early SIBERIA Clinical Trial Results to be Featured in an e-Course at EuroPCR
6/25/2020
In a head-to-head evaluation, significantly fewer silent brain infarcts were associated with CGuard™ EPS versus Acculink™ at 30 days post-procedure
-
Clinical Catch-Up: June 8-12
6/15/2020
It was a fairly busy week with clinical trial updates and announcements. Here’s a look. -
InspireMD Announces Publication of 12-Month Results of CGuard™ EPS PARADIGM Trial in EuroIntervention
6/10/2020
Results indicate that 12 months after carotid intervention the CGuard EPS MicroNET-covered stent delivers sustained protection against postprocedural neurologic events TEL AVIV, Israel, June 10, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease treatment, announced today that 12-month PARADIGM trial results have been published in the EuroIntervention journal